Skip to content

South Africa logo

Main menu
  • About Us
  • Our Leaders
    • Media
    • Pink Couch
      • Menopause
    • Cholesterol
    • Hypertension

Contact Us

Visit Organon's Twitter Opens a new window Visit Organon's Facebook Opens a new window Visit Organon's LinkedIn Opens a new window Visit Organon's Instagram Opens a new window

Back
English
Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Here for her health Press Release

Our latest news

Press Release

IMPORTANT MEDICINE SAFETY INFORMATION

RE: TOPICAL CORTICOSTEROIDS – RISK OF WITHDRAWAL REACTIONS Organon South Africa (Pty) Ltd as directed by the South African Health Products Regulatory Authority (SAHPRA), would like to inform you of the risk of withdrawal reactions associated with inappropriate and long-term use of topical corticosteroids. The Professional Information (PI) and Patient Information Leaflet (PIL) of topical corticosteroid containing medicines will be amended to reflect the above safety information.

IMPORTANT MEDICINE SAFETY INFORMATION
Contact our media team

For media related inquiries, please contact the appropriate team member below.

Luyanda Msiya
Assoc. Dir, Global Communications

luyanda.msiya@organon.com

Illustration of one hand holding globe with scene of stream and mountains and a second hand holding a building representing ESG efforts at sustainability

Company fact sheet

Learn the details of our company

See company fact sheet

Organon Social Media Channels

Linkedin icon Opens a new window Twitter icon Opens a new window Facebook icon Opens a new window Instagram icon Opens a new window
South Africa logo
  • Global Privacy Policy
  • PAIA Manual
© 2025 Organon South Africa (Pty) Lt (Reg. No. 2020/543929/07); Nexus 1, 3rd Floor, 44 Magwa Crescent, Waterfall City, Midrand, 2090; In case you need any update, or you have an inquiry or need to report an adverse event, you can contact Tel: +27871069655. Email: dpoc.zaf@organon.com ZA-NON-110110
TRUSTe Opens a new window TRUSTe Opens a new window

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept